Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

Paris, France: 27 July 2023Ipsen , a global specialty-care biopharmaceutical company, presents today its financial results for the first half of 2023. H1 2023 total sales up by 7.4% at CER1 , with...

Related Keywords

Shanghai ,China ,Saclay ,France General ,France ,Paris ,London ,City Of ,United Kingdom ,Cambridge ,Cambridgeshire ,United States ,American ,David Loew ,Nicolas Bogler ,Ioana Piscociu ,Amy Wolf ,Ipsen Euronext ,Metabolic Drugs Advisory Committee ,European Medicine Agency ,Committee For Medicinal Products Human Use ,European Commission ,Committee For Orphan Medicinal Products ,Drug Administration ,Net Profit ,Chief Executive Officer ,Rare Disease ,New Drug Application ,Prescription Drug User Fee Act ,Medicinal Products ,Human Use ,Orphan Medicinal Products ,Investor Relations ,Consumer Healthcare ,Sponsored Level ,American Depositary Receipt ,Corporate Brand Strategy ,Global Media ,